Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 3/20 | 0.50 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CASR | P41180 | 4/20 | 0.44 |
| ▸ | METAP2 | P50579 | 3/20 | 0.43 |
| ▸ | METAP1 | P53582 | 3/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1574391 | 0.90 | SSTR4 (0.51) | SSTR4GPR139LMNAGAACASR | |
| SCHEMBL1575083 | 0.88 | GPR139 (0.49) | SSTR4GPR139LMNAGAACASR | |
| SCHEMBL1575505 | 0.88 | SSTR4 (0.49) | SSTR4GPR139LMNAGAACASR | |
| SCHEMBL1575278 | 0.86 | SSTR4 (0.51) | SSTR4GPR139LMNAGAACASR | |
| SCHEMBL1574494 | 0.85 | SSTR4 (0.50) | SSTR4GPR139LMNAGAACASR | |
| SCHEMBL1574698 | 0.82 | SSTR4 (0.47) | SSTR4GPR139LMNAGAACASR | |
| SCHEMBL1574969 | 0.82 | KDM4E (0.54) | LMNA | |
| SCHEMBL1575039 | 0.82 | SSTR4 (0.45) | SSTR4GPR139CASRMETAP2METAP1 | |
| SCHEMBL1574959 | 0.81 | SSTR4 (0.48) | SSTR4GPR139LMNAGAACASR | |
| SCHEMBL1574677 | 0.80 | GPR139 (0.44) | SSTR4GPR139CASRMETAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511159-B2 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1698375-A1 | AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | EDNRA, LIPG, EDNRB | SSTR4 771/4885GPR139 347/4885LMNA 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.